These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 28122562

  • 1. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
    Lu X, Smare C, Kambili C, El Khoury AC, Wolfson LJ.
    BMC Health Serv Res; 2017 Jan 26; 17(1):87. PubMed ID: 28122562
    [Abstract] [Full Text] [Related]

  • 2. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K, Firnhaber C, Conradie F, Ndjeka N, Sinanovic E.
    Appl Health Econ Health Policy; 2018 Feb 26; 16(1):43-54. PubMed ID: 28980217
    [Abstract] [Full Text] [Related]

  • 3. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
    Mpobela Agnarson A, Williams A, Kambili C, Mattson G, Metz L.
    Expert Rev Anti Infect Ther; 2020 May 26; 18(5):475-483. PubMed ID: 32186925
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D, Dass R, Hettle R.
    BMC Health Serv Res; 2017 Mar 08; 17(1):182. PubMed ID: 28270207
    [Abstract] [Full Text] [Related]

  • 5. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis.
    Schnippel K, Firnhaber C, Page-Shipp L, Sinanovic E.
    Int J Tuberc Lung Dis; 2018 Aug 01; 22(8):918-925. PubMed ID: 29991402
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK.
    Wolfson LJ, Walker A, Hettle R, Lu X, Kambili C, Murungi A, Knerer G.
    PLoS One; 2015 Aug 01; 10(3):e0120763. PubMed ID: 25794045
    [Abstract] [Full Text] [Related]

  • 7. Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis.
    Ionescu AM, Mpobela Agnarson A, Kambili C, Metz L, Kfoury J, Wang S, Williams A, Singh V, Thomas A.
    Expert Rev Pharmacoecon Outcomes Res; 2018 Dec 01; 18(6):677-689. PubMed ID: 30073886
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
    Gomez GB, Siapka M, Conradie F, Ndjeka N, Garfin AMC, Lomtadze N, Avaliani Z, Kiria N, Malhotra S, Cook-Scalise S, Juneja S, Everitt D, Spigelman M, Vassall A.
    BMJ Open; 2021 Dec 03; 11(12):e051521. PubMed ID: 34862287
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia.
    Floyd K, Hutubessy R, Kliiman K, Centis R, Khurieva N, Jakobowiak W, Danilovits M, Peremitin G, Keshavjee S, Migliori GB.
    Eur Respir J; 2012 Jul 03; 40(1):133-42. PubMed ID: 22362862
    [Abstract] [Full Text] [Related]

  • 11. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany.
    Diel R, Hittel N, Schaberg T.
    Respir Med; 2015 May 03; 109(5):632-41. PubMed ID: 25862597
    [Abstract] [Full Text] [Related]

  • 12. Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis.
    Ryckman TS, Schumacher SG, Lienhardt C, Sweeney S, Dowdy DW, Mirzayev F, Kendall EA.
    Lancet Glob Health; 2024 Jun 03; 12(6):e995-e1004. PubMed ID: 38762299
    [Abstract] [Full Text] [Related]

  • 13. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO, Blok N, Okpokoro E, Dutt S, Akolo C, Dakum P, Abimiku A.
    PLoS One; 2020 Jun 03; 15(12):e0241065. PubMed ID: 33259492
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of treating multidrug-resistant tuberculosis.
    Resch SC, Salomon JA, Murray M, Weinstein MC.
    PLoS Med; 2006 Jul 03; 3(7):e241. PubMed ID: 16796403
    [Abstract] [Full Text] [Related]

  • 15. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis.
    Fitzpatrick C, Floyd K.
    Pharmacoeconomics; 2012 Jan 03; 30(1):63-80. PubMed ID: 22070215
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the Republic of Korea.
    Park HY, Ku HM, Sohn HS, Seo HS, Yung Lee H, Hwa Lim K, Kwon JW.
    Clin Ther; 2016 Mar 03; 38(3):655-67.e1-2. PubMed ID: 26907504
    [Abstract] [Full Text] [Related]

  • 17. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
    James LP, Klaassen F, Sweeney S, Furin J, Franke MF, Yaesoubi R, Chesov D, Ciobanu N, Codreanu A, Crudu V, Cohen T, Menzies NA.
    PLoS Med; 2024 May 03; 21(5):e1004401. PubMed ID: 38701084
    [Abstract] [Full Text] [Related]

  • 18. Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.
    Laurence YV, Griffiths UK, Vassall A.
    Pharmacoeconomics; 2015 Sep 03; 33(9):939-55. PubMed ID: 25939501
    [Abstract] [Full Text] [Related]

  • 19. Bedaquiline-based treatment for extensively drug-resistant tuberculosis in South Africa: A cost-effectiveness analysis.
    Fekadu G, Yao J, You JHS.
    PLoS One; 2022 Sep 03; 17(8):e0272770. PubMed ID: 35930574
    [Abstract] [Full Text] [Related]

  • 20. Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness.
    Nsengiyumva NP, Campbell JR, Oxlade O, Vesga JF, Lienhardt C, Trajman A, Falzon D, Den Boon S, Arinaminpathy N, Schwartzman K.
    PLoS Med; 2022 Jun 03; 19(6):e1004032. PubMed ID: 35696431
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.